Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 ProMetic Receives Octapharma PO | Contract Pharma

What are you searching for?

Sign in
Breaking News

ProMetic Receives Octapharma PO

To supply $48M of PrioClear for Octaplas product

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

ProMetic Life Sciences Inc. has received a $4.8 million purchase order under its ongoing supply agreement with Octapharma, a Swiss based plasma fractionation company that specializes in human proteins. The order relates to the purchase of PrioClear, a prion capture resin incorporated into Octapharma’s manufacturing process for its solvent/detergent treated plasma product, Octaplas. Octaplas is currently approved for marketing in the U.S. and several European countries.

“This new purchase order confirms our growth forecast for shipments to Octapharma. We anticipate further growth in the coming years as they continue to gain market share in more mature markets and grow their sales in newer markets. We are pleased to see our class leading products and technologies contribute additional safety benefits to the patients,” said Mr. Pierre Laurin, president and chief executive officer of ProMetic Life Sciences.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters